Navigation Links
NewCardio Study Shows CardioBip Detects Recurrent Atrial Fibrillation Earlier and More Reliably than Periodic Holter Monitoring
Date:2/24/2011

nce for our belief that CardioBip is exceptionally well-suited for long-term cardiac monitoring. There are more than 30 million patients – in the US and throughout the world - who have atrial fibrillation or other cardiac arrhythmias, and could benefit from using the CardioBip solution. We look forward to sharing the data with our HRS colleagues, and to building market awareness of CardioBip's efficacy, ease of use, and suitability for this important clinical need."

In the study, 21 patients who underwent catheter ablation for AF were given CardioBip devices and asked to provide daily transmissions for 60 days and additional transmissions whenever symptoms (such as palpitations or dizziness) developed. Patients also had 24-hour, continuous 12-lead ECG recordings (Holter monitors [HM]), a commonly-used method for AF surveillance, at 30 and 60 days post-procedure. Both CardioBip and HM data were reviewed by two independent, blinded cardiologists.

All 21 patients completed the full 60-day follow-up period and showed good compliance throughout, making an average of 2.2 transmissions per day. Twenty of 21 patients had at least one episode of recurrent AF detected by CardioBip. Most of these episodes were asymptomatic. Six of the 20 patients also had occurrence of atrial flutter (AFLT) detected. In contrast, only four and two patients had recurrent AF and AFLT detected by 12-lead HM, respectively. In all these six patients, AF and AFLT had already been detected by CardioBip – an average of 27 days earlier than detection by 12-lead HM. All symptomatic CardioBip transmissions were correlated with at least one rhythm irregularity (e.g. AF, AFLT, or premature beats).

Dr. Dorin Panescu, PhD, NewCardio's Chief Technical Officer, commented, "This is the third clinical study showing that CardioBip is an effective, accurate and patient-friendly solution for long-term monitoring of cardiac conditions. In particular, the study data show that CardioBi
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NewCardio Study of QTinno Accuracy Selected for Presentation at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics
2. NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study
3. NewCardios Chief Technical Officer, Dr. Dorin Panescu, Named 2011 IEEE Fellow
4. NewCardio Announces Financial Results for Its 2010 Third Quarter
5. NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded Testing Dataset
6. NewCardio CEO Increases Equity Position
7. NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress
8. NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
9. NewCardio Announces Master Services Agreement With Dedicated Phase I
10. NewCardio Leadership to Present Two Abstracts at ISCE Conference
11. Vincent W. Renz Joins NewCardio as President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... it has filed a premerger notification under the ... the U.S. Federal Trade Commission (FTC) relating to ... About Valeant Pharmaceuticals International, Inc. ... VRX) is a multinational specialty pharmaceutical company that ...
(Date:7/14/2014)... , July 14, 2014 Synthetic ... technology partnership with global bioengineering leader DNA2.0, ... for quick-to-market products. The integration ... machine learning optimization technologies, such as ProteinGPS™ ... process of engineering proteins in the Pareto ...
(Date:7/14/2014)... 2014  Abbott (NYSE: ABT) announced today that it will ... Mylan for equity ownership of a newly formed entity ... Abbott,s developed markets pharmaceuticals business, and will ... of approximately $5.3 billion based on Mylan,s closing stock ... business generated approximately $2 billion in sales in 2013. ...
Breaking Medicine Technology:Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 4Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 5Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 2Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 4Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 5Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 6Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 7
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA ), ... it has filed its Annual Report on Form 20-F with ... December 31, 2010 on April 22, 2011.  The Annual Report ... The Company will provide a hard copy of ...
... The following release is being issued by law ... Feldman & Pinto: According to two new ... Medical Journal, Bayer,s birth control pills Yaz and Yasmin, ... triple the risk of serious blood clots (known as ...
Cached Medicine Technology:Sinovac Files Annual Report on Form 20-F 2
(Date:7/14/2014)... 14, 2014 Top nutritional supplement provider ... its Quality Control and Assurance Department. As the company ... additional, highly-qualified quality assurance (QA) and quality control (QC) ... which IQ Formulations has become known. , ... decades of stellar experience and qualifications to their new ...
(Date:7/14/2014)... SingaporeA*STAR,s Bioprocessing Technology Institute (BTI) has entered into ... pharmaceutical company, Roche, to identify novel drug candidates ... partnership brings together BTI,s capabilities in novel antibody ... (mAbs) therapeutics, opening up the possibility of ... death worldwide. , The collaboration makes use ...
(Date:7/14/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... MARKETS , the global synthetic biology market is ... 2018, with a five-year compound annual growth rate ... fastest growing segment, with anticipated $9.7 billion in ... the pharmaceutical/diagnostics, chemical, energy, and agricultural industries compose ...
(Date:7/14/2014)... Botanica Day Spa announced last month ... held at the day spa in down town Clearwater, ... and other refreshments will be served as clients are ... beauty products and great deals on spa services, ... , Dermaplaning (also known as “facial shaving”) is a ...
(Date:7/14/2014)... -- Along with improving vision, cataract surgery may slow ... types of dementia, a new study suggests. Better ... said. "These preliminary results indicate that improved vision ... dementia and their loved ones, both visual and non-visual," ... and University Hospitals Case Medical Center, in Ohio. ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Expands Quality Control and Assurance Department 2Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2
... SOUTH SAN FRANCISCO, Calif., May 13 Rigel Pharmaceuticals, Inc. ... Gower, the company,s chairman and chief executive officer, is scheduled ... Securities Research Conference in San Francisco on Wednesday, May 20th ... the subsequent archived recording, log on to www.rigel.com . ...
... Science Olympiad to Emphasize the Importance of Fueling Body ... you find America,s brightest young minds launching rockets, crashing ... are part of the 25th annual Science Olympiad National ... first time, the incredible edible egg, on behalf of ...
... Gastroenterologist Offers Tips for Treatment , ... San Bruno, CA (PRWEB) May ... (AGE) affect Americans each year, according to eMedicine from WebMD. ... a viral, bacterial or parasitic infection. Victims are usually hit by ...
... medical search engine will debut on 16 May 2009 at the ... , ... Budapest, Hungary (PRWEB) May 13, 2009 -- Existing ... information to consumers. WebLib CEO Endre Jofoldi notes that "the goal ...
... ( BOVESPA: AMIL3, Bloomberg: AMIL3 BZ and Reuters: AMIL3.SA ... its results for the first quarter of 2009. ... stood at 3.11 million, 9.7% up on the 1Q08 ... 4Q08.Adjusted Operating Revenues totaled R$ 1,131 million in ...
... Adding B vitamin to grain products cut congenital heart defects ... -- Since the mandatory addition of folic acid to flour, ... than a decade ago, fewer babies have been born with ... of vitamin B, has been shown to reduce neural tube ...
Cached Medicine News:Health News:America's Top Young Scientists to Receive Scholarships for Winning Eggs-Periments 2Health News:America's Top Young Scientists to Receive Scholarships for Winning Eggs-Periments 3Health News:America's Top Young Scientists to Receive Scholarships for Winning Eggs-Periments 4Health News:When Stomach Flu Strikes, Work With, Not Against, Body's Natural Defenses 2Health News:Amilpar - Revenue Increases 13.4% and Medical Loss Ratio Falls in the First Quarter 2009 2Health News:Folic Acid Reduces Infant Heart Defects 2
Sheath Introducers with guidewires....
... design, utilizing an advanced cobalt-based ... stainless steel stents. This stronger ... for unparalleled flexibility plus optimal ... Stent Systemwith thin struts that ...
... Catheter provides support to enhance the ... adverse conditions. It gives you dependable ... your destination in cardiac interventions. It ... of clinical situations and the most ...
... Xtra, and Maximum ACT introducers represent ... specialty hemostasis introducers in the world. ... hemostasis introducers for use in interventional ... angioplasty, stenting, atherectomy, temporary pacing, endomyocardial ...
Medicine Products: